Skip to main content
. Author manuscript; available in PMC: 2013 Aug 14.
Published in final edited form as: Clin Cancer Res. 2012 Jun 18;18(16):4465–4472. doi: 10.1158/1078-0432.CCR-12-0286

Figure 3.

Figure 3

A, Kaplan–Meier curves for DFS among ER+ (local assessment) patients for tamoxifen versus placebo. B, Kaplan–Meier curves for DFS among luminal subtypes by immunohistochemistry for tamoxifen versus placebo. C, Kaplan–Meier curves for DFS among luminal subtypes by PAM50 for tamoxifen versus placebo.